Abstract
Breast cancer is the commonest type of malignant tumor in women, comprising of about 30% of all cancers in women worldwide. In the past decades, the mortality of breast cancer patients has significantly been reduced due to the adoption of periodic breast cancer screening and the emergence of various treatments, such as radiotherapy, chemotherapy, and surgery. Currently, chemotherapy is one of the most effective treatments for breast cancer. Its side effects, however, pose a long-term challenge on a patient’s health. Thus, it is highly desirable to develop new therapies that can specifically target carcinoma cells without damaging normal and healthy cells. Tremendous efforts have been made to develop targeted drug delivery systems for breast cancer treatment. In this review, we intend to systematically examine recent progresses made along these directions. We highlighted various delivery carriers designed for directing the diffusion of therapeutic agents inside tumors to kill or suppress breast cancer cells. These carriers include molecular-recognitionelement modified anticancer agents, stem cells that have tropism to breast cancers, nanoparticle-based anticancer drugs, and anticancer peptides. In particular, we discussed recent patents on the new targeted therapeutic delivery systems, with an emphasis on triple-negative breast cancer therapies.
Keywords: Breast cancer, metastasis, stem cells, targeted drug delivery, treatment, tumor
Recent Patents on Anti-Cancer Drug Discovery
Title:Targeted Drug Delivery for Breast Cancer Treatment
Volume: 8 Issue: 2
Author(s): Sha Jin and Kaiming Ye
Affiliation:
Keywords: Breast cancer, metastasis, stem cells, targeted drug delivery, treatment, tumor
Abstract: Breast cancer is the commonest type of malignant tumor in women, comprising of about 30% of all cancers in women worldwide. In the past decades, the mortality of breast cancer patients has significantly been reduced due to the adoption of periodic breast cancer screening and the emergence of various treatments, such as radiotherapy, chemotherapy, and surgery. Currently, chemotherapy is one of the most effective treatments for breast cancer. Its side effects, however, pose a long-term challenge on a patient’s health. Thus, it is highly desirable to develop new therapies that can specifically target carcinoma cells without damaging normal and healthy cells. Tremendous efforts have been made to develop targeted drug delivery systems for breast cancer treatment. In this review, we intend to systematically examine recent progresses made along these directions. We highlighted various delivery carriers designed for directing the diffusion of therapeutic agents inside tumors to kill or suppress breast cancer cells. These carriers include molecular-recognitionelement modified anticancer agents, stem cells that have tropism to breast cancers, nanoparticle-based anticancer drugs, and anticancer peptides. In particular, we discussed recent patents on the new targeted therapeutic delivery systems, with an emphasis on triple-negative breast cancer therapies.
Export Options
About this article
Cite this article as:
Jin Sha and Ye Kaiming, Targeted Drug Delivery for Breast Cancer Treatment, Recent Patents on Anti-Cancer Drug Discovery 2013; 8 (2) . https://dx.doi.org/10.2174/1574892811308020003
DOI https://dx.doi.org/10.2174/1574892811308020003 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Comparing High LET <sup>227</sup>Th- and Low LET <sup>177</sup>Lu-trastuzumab in Mice with HER-2 Positive SKBR-3 Xenografts
Current Radiopharmaceuticals The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines
Current Topics in Medicinal Chemistry Recent Approaches and Success of Liposome-Based Nano Drug Carriers for the Treatment of Brain Tumor
Current Drug Delivery Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective
Current Pharmaceutical Design Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Current Drug Targets Targeting Platinum Resistant Disease in Ovarian Cancer
Current Medicinal Chemistry Nanomedicine: Potential Devices for Diagnostics
Recent Patents on Nanomedicine Cancer Biomarker Discovery for Precision Medicine: New Progress
Current Medicinal Chemistry Anthocyanins As Modulators of Cell Redox-Dependent Pathways in Non-Communicable Diseases
Current Medicinal Chemistry Gene Expression Profiles in Breast Cancer to Identify Estrogen Receptor Target Genes
Mini-Reviews in Medicinal Chemistry Rho GTPase Effector Functions in Tumor Cell Invasion and Metastasis
Current Drug Targets Estrogenic Compounds, Estrogen Receptors and Vascular Cell Signaling in the Aging Blood Vessels
Current Medicinal Chemistry Molecular Signals Elicited by GPCR Agonists in Hypertension, Cardiovascular Remodeling: Are MMPs and ADAMs Elusive Therapeutic Targets?
Current Hypertension Reviews Concentration-Dependent Mechanisms of Adverse Drug Reactions in Epilepsy
Current Pharmaceutical Design Marine Drugs: A Hidden Wealth and a New Epoch for Cancer Management
Current Drug Metabolism Overview
Anti-Cancer Agents in Medicinal Chemistry Naphthalimides and Azonafides as Promising Anti-Cancer Agents
Current Medicinal Chemistry Neurokinin-1 Receptor Antagonist Can Prevent the Delayed Phase in Patients: A Single Center Retrospect Study
Anti-Cancer Agents in Medicinal Chemistry Trace Determination of Tamoxifen using Optimized Solvent Bar Microextraction and HPLC-UV
Current Pharmaceutical Analysis The Role of Protein Kinase C-alpha (PKC-α) in Cancer and its Modulation by the Novel PKC-α-Specific Inhibitor Aprinocarsen
Current Pharmaceutical Design